首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1544183

血液筛检市场规模、份额、成长分析：按产品和服务、按技术、按最终用户、按地区 - 行业预测，2024-2031 年

Blood Screening Market Size, Share, Growth Analysis, By Product Type (Reagents & Kits, Instruments), By Technology (Nucleic Acid Test (NAT), Rapid Tests), By End User (Hospitals & Clinics, Diagnostic Centers), By Region - Industry Forecast 2024-2031

出版日期: 2024年08月24日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计2022年全球血液筛检市场规模将达30.4亿美元，从2023年的33亿美元增加至2031年的63.3亿美元，复合年增长率预计将成长8.50%。

血液筛检自动化分子平台正在推动市场的显着成长，业界领先的公司纷纷采用这项技术。促成这一市场扩张的主要因素包括捐血和捐血数量的增加、血液安全意识的提高、感染疾病发病率的上升以及政府的各种措施。该市场还受益于大型手术的频率，尤其是输血，这对于治疗儿童贫血、创伤和先天性血液疾病至关重要。根据我们的分析，全球每年进行超过 2.34 亿例大型手术，需要频繁输血。全球约有1.185亿次捐血，其中40%来自高所得国家，占全球捐血的16%。不同收入水准的捐血分布不同，高所得国家占31.5%，中高收入国家占15.9%，中低收入国家占6.8%，低收入国家占5.0%。在主要产业参与者之间的策略伙伴关係的推动下，诊断测试领域有望实现显着成长。这些合作伙伴关係预计将增加先进诊断测试的可用性。例如，2023年3月，TruDiagnostic与专门从事NAD诊断的芬兰公司NADMED合作，在美国推出创新的NAD+血液诊断测试。此次合作凸显了诊断能力扩大和市场成长的不断成长趋势。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Abbott Laboratories（USA）
Becton, Dickinson and Company（USA）
Bio-Rad Laboratories, Inc.（USA）
bioMerieux SA（France）
F. Hoffmann-La Roche Ltd.（Switzerland）
Grifols, SA（Spain）
Hologic, Inc.（USA）
Immucor, Inc.（USA）
Meridian Bioscience, Inc.（USA）
Ortho Clinical Diagnostics（USA）
Quotient Limited（UK）
Siemens Healthineers AG（Germany）
Sysmex Corporation（Japan）
Thermo Fisher Scientific Inc.（USA）
Danaher Corporation（USA）
Grifols Diagnostic Solutions Inc.（USA）
Haemonetics Corporation（USA）
Luminex Corporation（USA）
Natera, Inc.（USA）
Novartis International AG（Switzerland）
PerkinElmer, Inc.（USA）
Promega Corporation（USA）

简介目录

Product Code: SQMIG35J2044

Global Blood Screening Market size was valued at USD 3.04 Billion in 2022 and is poised to grow from USD 3.30 Billion in 2023 to USD 6.33 Billion by 2031, at a CAGR of 8.50% during the forecast period (2024-2031).

Automated molecular platforms for blood screening are driving significant growth in the market, as leading industry players adopt this technology. Key factors fueling this expansion include the increasing number of blood donations and donors, heightened awareness of blood safety, the rising incidence of infectious diseases, and various government initiatives. The market is also benefiting from the frequency of blood transfusions, which are essential in major surgeries, particularly in managing childhood anemia, trauma, and congenital blood disorders. Based on our analysis, over 234 million major surgeries are conducted globally each year, necessitating frequent blood transfusions. Our study also reveals that approximately 118.5 million blood donations occur worldwide, with 40% coming from high-income countries, which contribute to 16% of global donations. The distribution of donations varies by income level, with high-income countries accounting for 31.5% of donations, upper-middle-income countries 15.9%, lower-middle-income countries 6.8%, and low-income countries 5.0%. The diagnostic testing landscape is poised for substantial growth, driven by strategic partnerships among key industry players. These collaborations are expected to enhance the availability of advanced diagnostic tests. For instance, in March 2023, TruDiagnostic partnered with NADMED, a Finnish company specializing in NAD diagnostics, to launch an innovative NAD+ blood diagnostic test in the U.S. This partnership highlights the increasing trend towards expanding diagnostic capabilities and market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Blood Screening market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Blood Screening Market Segmental Analysis

Global Blood Screening Market is segmented based on product type, technology, end users, and region. Based on product & service, the market is segmented into Reagents & Kits [NAT Reagents & Kits, ELISA Reagents & Kits, Other Reagents & Kits], Instruments [Rental Purchase, Outright Purchase], Software & Services. Based on technology, the market is segmented into Nucleic Acid Test (NAT) [Transcription-mediated Amplification (TMA), Real-time Polymerase Chain Reaction (RT-PCR)], Serology/Immunoassay [Chemiluminescent Immunoassays (CLIA), Fluorescent Immunoassays (FIA), Colorimetric Immunoassays/ELISA (CI/ELISA)], Rapid Tests, Western Blot Assays, Next-generation Sequencing (NGS). Based on end user, the market is segmented into hospitals & clinics, diagnostic centres, and blood banks. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Blood Screening Market

Awareness among healthcare professionals and patients regarding the risks of blood transfusions, such as the transmission of infectious diseases, is increasing. This heightened awareness is driving a greater demand for blood screening products that ensure the safety of blood and blood products. Additionally, the growing prevalence of blood-related disorders and the rising need for blood and blood products for various medical procedures, including transfusions and surgeries, are contributing to the expansion of the blood screening market. This demand underscores the need for effective screening solutions to enhance safety and manage the risks associated with blood transfusions.

Restraints in the Global Blood Screening Market

The shortage of phlebotomists, laboratory technicians, and other skilled professionals could hinder the widespread adoption of blood screening products. Healthcare organizations and blood banks may face difficulties in finding qualified personnel to operate the equipment and conduct the tests, potentially limiting their ability to implement blood screening programs effectively. This workforce gap poses a significant challenge to expanding the use of blood screening technologies and ensuring their widespread availability.

Market Trends of the Global Blood Screening Market

The rising demand for plasma-derived products, including immunoglobulins and clotting factors, is significantly boosting the need for blood screening products that ensure the safety of these essential therapies. As plasma-derived treatments continue to expand into new therapeutic areas, the demand for reliable blood screening solutions is expected to grow. In the United States, the increasing prevalence of chronic diseases such as cancer, diabetes, and thyroid disorders is anticipated to further drive market growth. The American Cancer Society's "Cancer Facts and Figures 2023" report projects around 1.9 million new cancer cases for the year, with prostate cancer being the most common, followed by lung and female breast cancers. Similarly, data from the Government of Canada reported 233,900 new cancer diagnoses, with prostate cancer remaining the most prevalent. This rising cancer burden is likely to boost the demand for blood testing services, supporting market expansion throughout the forecast period.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors of The Market
Degree Of Competition
Top Investment Pockets
Market Attractive Index
Ecosystem Mapping
Patent Analysis
Pricing Analysis
Trade Analysis
Consumer And Buying Criteria
Regulatory Analysis
Technology Analysis
Case study Analysis

Global Blood Screening Market by Product and services

Market Overview
Reagents and kits
- NAT reagents and kits
- Elisa reagents and kits
- Other Reagents and kits
Instruments
- Rental purchase
- Outright purchase
Software and services

Global Blood Screening Market by Technology

Market Overview
Nucleic acid test
- Transcription-mediated Amplification
- Real-time PCR
Serology/Immunoassay
- Chemiluminescent Immunoassays
- Fluorescent Immunoassays
- Colorimetric Immunoassays/ELISA
Rapid Tests
Western Blot Assays
Next-generation Sequencing

Global Blood Screening Market by End-user

Market Overview
Hospitals & Clinics
Diagnostic centers
Blood Banks

Global Blood Screening Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Immucor, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Meridian Bioscience, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ortho Clinical Diagnostics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quotient Limited (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols Diagnostic Solutions Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Haemonetics Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Luminex Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Promega Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments